Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N′-[(4-chlorophenyl)-sulfonyl]- 4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 963-968

  Srivastava, Brijesh Kumar ^a   Soni, Rina ^a   Joharapurkar, Amit ^a   Sairam, Kalapatapu V V M ^a   Patel, Jayendra Z ^a   Goswami, Amitgiri ^a   Shedage, Sandeep A ^a   Kar, Sidhartha S ^a   Salunke, Rahul P ^a   Gugale, Shivaji B ^a   Dhawas, Amol ^a   Kadam, Pravin ^a   Mishra, Bhupendra ^a   Sadhwani, Nisha ^a   Unadkat, Vishal B ^a   Mitra, Prasenjit ^a   Jain, Mukul R ^a   Patel, Pankaj R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Bioisosteric replacement; CB1 receptor antagonist; Conformational analysis; Homology model; Imidazole; Oxazole

Indexed keywords

4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; IMIDAZOLE; OXAZOLE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; EVOLUTIONARY HOMOLOGY; FEMALE; NONHUMAN; RAT;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXAZOLES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 38849134932     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.036     Document Type: Article

References (30)

1. Harrold J., Pinkney J., and Williams G. Drug Discovery Today: Ther. Strat. 1 (2004) 219
2. Sorbera L.A., Castaner J., and Silvestre J.S. Drugs Future 30 (2005) 128
3. Hertzog D.L. Expert Opin. Ther. Pat. 14 (2004) 1435
4. Lange J.H.M., and Kruse C.G. Drug Discovery Today 10 (2005) 693
5. Muccioli G.G., and Lambert D.M. Curr. Med. Chem. 12 (2005) 1361
6. Lange J.H.M., Coolen H.K.A.C., van Stuivenberg H.H., Dijksman J.A.R., Herremans A.H.J., Ronken E., Keizer H.G., Tipker K., McCreary A.C., Veerman W., Wals H.C., Stork B., Verveer P.C., den Hartog A.P., de Jong N.M.J., Adolfs T.J.P., Hoogendoorn J., and Kruse C.G. J. Med. Chem. 47 (2004) 627
7. Need A.B., Davis R.J., Alexander-Chacko J.T., Eastwood B., Chernet E., Phebus L.A., Sindelar D.K., and Nomikos G.G. Psychopharmacology 184 (2006) 26
8. Bostrom J., Berggren K., Elebring T., Greasley P.J., and Wilstermann M. Bioorg. Med. Chem. 15 (2007) 4077
9. Plummer C.W., Finke P.E., Mills S.G., Wang J., Tong X., Doss G.A., Fong T.M., Lao J.Z., Schaeffer M.T., Chen J., Shen C.P., Stribling D.S., Shearman L.P., Strack A.M., and Van der Ploeg L.H.T. Bioorg. Med. Chem. Lett. 15 (2005) 1441
10. Lange J.H.M., van Stuivenberg H.H., Coolen H.K.A.C., Adolfs T.J.P., McCreary A.C., Keizer H.G., Wals H.C., Veerman W., Borst A.J.M., de Looff W., Verveer P.C., and Kruse C.G. J. Med. Chem. 48 (2005) 1823
11. Lange, J. H. M.; Kruse, C. G.; van Stuivenberg, H. H. US Patent 05/0171179, 2005; Chem. Abstr. 2005, 143, 172869.
12. Srivastava B.K., Joharapurkar A., Raval S., Patel J.Z., Soni R., Raval P., Gite A., Goswami A., Sadhwani N., Patel H., Mishra B., Solanki M., Pandey B., Jain M.R., and Patel P.R. J. Med. Chem. 50 (2007) 5951
13. Lohray, B. B.; Lohray, V. B.; Jain, M. R.; Srivastava, B. K. US Patent 2006/0025448, 2006; Chem. Abstr. 2006, 144, 164295.
14. Lohray, B. B.; Lohray, V. B.; Srivastava, B. K. WO Patent 2006/025069, 2006; Chem. Abstr. 2006, 144, 292751.
15. Srivastava B.K., Jain M., Joharapurkar A., Raval S., Patel J.Z., Raval P., Soni R., Sadhwani N., and Patel P.R. Med. Chem. Res. 15 (2007) 75
16. Sadhwani N., Jain S., Metiya S., Pandya P., Kanani D., Shah S., Srivastava B.K., and Mitra P. Med. Chem. Res. 15 (2007) 216
17. Joharapurkar, A.; Srivastava, B. K.; Mitra, P.; Jain, M. R.; Patel, P. R. Poster No. 208, Keystone Symposia on Molecular and Cellular Biology, Obesity: Peripheral and Central Pathways Regulating Energy Homeostasis, Obesity (J2) www.keystonesymposia.org, January 14-19, 2007; Keystone, CO, USA.
18. +.
19. Lange, J. H. M.; Kruse, C. G.; van Stuivenberg, H. H. WO Patent 2005/080345, 2005; Chem. Abstr. 2005, 143, 248389.
20. Levin J.I., Turos E., and Weinreb S.M. Synth. Commun. 12 (1982) 989
21. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. J. Med. Chem. 40 (1997) 1347
22. Garigipati R.S. Tetrahedron Lett. 31 (1990) 1969
23. Lange, J. H. M.; Coolen, H. K. A. C.; van Stuivenberg, H. H. US Patent 05/0171179, 2005; Chem. Abstr. 2005, 143, 172869.
24. 26 Cells grown to 80% confluence were maintained in HAM'S F12 medium containing 10% heat inactivated dialyzed fetal bovine serum and 0.8 mg/mL G-418. Cells were seeded at a density of 50,000 cells/well in 24-well plate, grown for 16-18 h, washed once with PBS and incubated for 30 min at 37 °C in plain HAM'S F12 containing 0.25% free fatty acid BSA, IBMX (0.1 mM) and RO20-1724 (0.1 mM). IBMX, the pan phosphodiesterase inhibitor and RO20-1724, the specific phosphodiesterase- 4 inhibitor were added to restore cAMP up to the detection limit. After 5 min incubation with the drugs, forskolin was added at a final concentration of 10 μM and incubation was carried out for another 20 min at 37 °C. The reaction was terminated by washing once with PBS and adding 200 μL lysis buffer comprising 0.1 N HCl and 0.1% Trition X-100. The lysates were centrifuged and aliquotes from supernatants were used for detection of cAMP by ELISA as per the manufacturer's protocol.
25. 5% Sucrose Solution Intake in Zucker fa/fa rats: All the animals used in the study were procured from the Animal Breeding Facility of Zydus Research Center. Institutional Animal Ethical Committee approved all the study protocols. Female Zucker fa/fa rats (age of 10-12 weeks and 300-350 g of weight) were used for in vivo experiments, compounds were suspended with 0.5% carboxymethylcellulose sodium salt in distilled water. The test compounds were administered at the dose of 10 mg/kg and by oral route in a volume of 2 mL/kg body weight. The obese Zucker fa/fa rats were housed individually and subjected to training for consuming 5% sucrose solution over a period of 4 h, by allowing access to the 5% sucrose solution in the bottles. Food and water were withdrawn during this time. This training was given for six consecutive days, at the same time of the day. On seventh day, the animals were randomized into groups of six animals each and treated with the test compounds. After one hour of treatment, the animals were exposed to the 5% sucrose solution for 4 h as that of the training schedule. The amount of sucrose solution consumed by each animal was calculated. Difference between the control and treatment groups were analyzed by performing one way ANOVA followed by Dunnett's test on sucrose solution consumption using Graph pad Prism software.
26. Rinaldi-Carmona M., Le Duigou A., Oustric D., Barth F., Bouaboula M., Carayon P., Casellas P., and Le Fur G. J. Pharmacol. Exp. Ther. 287 (1998) 1038
27. Harrold J.A., Elliott J.C., King P.J., Widdowson P.S., and Williams G. Brain Res. 952 (2002) 232
28. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., and Le Fur G. Psychopharmacology 132 (1997) 104
29. The energy minimization procedure adopted is smart minimizer protocol in Discovery Studio 1.6, where 100 cycles of minimization are allowed at steepest descent, conjugate gradient and Newton-Raphson methods. All the modeling procedures adopted in the study are molecular mechanics with Charm Force Field.
30. All the computations were carried out on Accelrys Inc. Discovery Studio 1.6. Accelrys Inc., San Diego, CA.